Kimozo

Temozolomide, the active ingredient in Kimozo, is an alkylating agent presented as an oral formulation for oral use. It is employed in the treatment of malignant brain tumors, specifically glioblastoma multiforme and anaplastic astrocytoma, in adult patients. The drug works by interfering with DNA replication in rapidly dividing tumor cells, leading to cell death and tumor control.

GNH USA supplies Kimozo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Temozolomide is used in oncology to treat high‑grade gliomas.

Glioblastoma multiforme: improves overall survival when combined with radiotherapy. Anaplastic astrocytoma: delays tumor progression and extends progression‑free survival. Recurrent high‑grade glioma: offers a therapeutic option after prior treatment failure.

Temozolomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Fatigue - Constipation - Headache - Alopecia

Serious or Rare Side Effects: - Bone marrow suppression (neutropenia, thrombocytopenia) - Severe infections - Liver toxicity (elevated transaminases) - Allergic reactions (rash, anaphylaxis) - Secondary malignancies

Before initiating therapy with Temozolomide, several safety considerations should be reviewed.

Blood count monitoring: perform complete blood count before each cycle. Liver function assessment: evaluate hepatic enzymes regularly. Renal function assessment: adjust if impaired. Pregnancy avoidance: contraindicated in pregnant women. Concomitant drug review: avoid drugs that further suppress marrow. Store at below 25°C: keep in the original pack, protect from moisture.

Temozolomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - Live vaccines: heightened infection risk.

Moderate Interactions (Monitor Closely): - Enzyme inducers (e.g., rifampin, carbamazepine): may reduce temozolomide exposure. - CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Anticonvulsants (e.g., phenytoin): may alter plasma levels.